<?xml version='1.0' encoding='utf-8'?>
<document id="28102731"><sentence text="Microfluidic whole blood testing of platelet response to pharmacological agents." /><sentence text="Platelets present a number of intracellular and transmembrane targets subject to pharmacological modulation, either for cardiovascular disease reduction or as an unintended drug response" /><sentence text=" Microfluidic devices allow human blood to clot on a defined surface under controlled hemodynamic and pharmacological conditions" /><sentence text=" The potencies of a number of antiplatelet and anticancer drugs have been tested with respect to platelet deposition on collagen under flow" /><sentence text=" Inhibitors of cyclooxygenase-1 (COX-1) reduce platelet deposition, either when added ex vivo to blood or ingested orally by patients prior to testing" /><sentence text=" Some individuals display a functional &quot;aspirin-insensitivity&quot; in microfluidic assay" /><sentence text=" When certain nonsteroidal anti-inflammatory drugs (NSAIDs) are taken orally, they block COX-1 acetylation by aspirin with concomitant reduction of aspirin efficacy against platelets in microfluidic assay"><entity charOffset="110-117" id="DDI-PubMed.28102731.s7.e0" text="aspirin" /><entity charOffset="148-155" id="DDI-PubMed.28102731.s7.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.28102731.s7.e0" e2="DDI-PubMed.28102731.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28102731.s7.e0" e2="DDI-PubMed.28102731.s7.e1" /></sentence><sentence text=" Both P2Y1 and P2Y12 inhibitors reduce platelet deposition under flow, as do NO donors and iloprost that target the guanylate cyclase and the prostacyclin receptor, respectively"><entity charOffset="77-79" id="DDI-PubMed.28102731.s8.e0" text="NO" /><entity charOffset="142-154" id="DDI-PubMed.28102731.s8.e1" text="prostacyclin" /><pair ddi="false" e1="DDI-PubMed.28102731.s8.e0" e2="DDI-PubMed.28102731.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28102731.s8.e0" e2="DDI-PubMed.28102731.s8.e1" /></sentence><sentence text=" In a microfluidic assay of 37 kinase inhibitors, dasatinib had potent antiplatelet activity, while bosutinib was less potent"><entity charOffset="50-59" id="DDI-PubMed.28102731.s9.e0" text="dasatinib" /><entity charOffset="100-109" id="DDI-PubMed.28102731.s9.e1" text="bosutinib" /><pair ddi="false" e1="DDI-PubMed.28102731.s9.e0" e2="DDI-PubMed.28102731.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28102731.s9.e0" e2="DDI-PubMed.28102731.s9.e1" /></sentence><sentence text=" Dasatinib and bosutinib have known profiles against numerous kinases, revealing overlapping and nonoverlapping activities relevant to their unique actions against platelets"><entity charOffset="1-10" id="DDI-PubMed.28102731.s10.e0" text="Dasatinib" /><entity charOffset="15-24" id="DDI-PubMed.28102731.s10.e1" text="bosutinib" /><pair ddi="false" e1="DDI-PubMed.28102731.s10.e0" e2="DDI-PubMed.28102731.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28102731.s10.e0" e2="DDI-PubMed.28102731.s10.e1" /></sentence><sentence text=" Also, dasatinib caused a marked and specific inhibition of GPVI signaling induced by convulxin, consistent with a dasatinib-associated bleeding risk"><entity charOffset="7-16" id="DDI-PubMed.28102731.s11.e0" text="dasatinib" /><entity charOffset="115-124" id="DDI-PubMed.28102731.s11.e1" text="dasatinib" /><pair ddi="false" e1="DDI-PubMed.28102731.s11.e0" e2="DDI-PubMed.28102731.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28102731.s11.e0" e2="DDI-PubMed.28102731.s11.e1" /></sentence><sentence text=" Microfluidic devices facilitate drug library screening, dose-response testing, and drug-drug interaction studies" /><sentence text=" Kinase inhibitors developed as anticancer agents may present antiplatelet activities that are detectable by microfluidic assay and potentially linked to bleeding risks" /><sentence text="" /></document>